[Hormonal therapy of constitutionally tall children]. 1998

W J de Waal, and S de Muinck Keizer-Schrama, and S L Drop
Academisch Ziekenhuis Rotterdam-Sophia Kinderziekenhuis, subafd. Endocrinologie.

Children of constitutionally tall stature may experience serious problems related to their height. Treatment with high dose sex steroids may be considered in order to limit final adult height. Prediction of adult height plays a central part in the management of children of tall stature. Various aspects of height prediction in children of tall stature are discussed. The height reducing effect varies between studies from 2 to 10 cm. Recently, in a large Dutch study the mean effects of therapy were 0.7 and 2.4 cm for boys and girls respectively. The effect depended on the bone age at start of treatment. Beyond a critical bone age of about 14 years treatment had no effect. Minimal age for intervention is 9.5-10 year for boys and 9.0-9.5 year for girls. Recommended treatment for boys is 250 mg testosterone esters i.m. per week and for girls ethinyloestradiol orally 200 micrograms per day in combination with medroxyprogesterone or dydrogesterone (both 5-10 mg per day) during the first 12-14 days of the cycle. Treatment has to be continued until complete closure of the epiphyses. While side effects during hormonal therapy are frequent, they are mostly temporary and mild and seldom lead to cessation of therapy. So far there have been no indications of adverse effects on, for instance, gonadal function.

UI MeSH Term Description Entries
D007273 Injections, Intramuscular Forceful administration into a muscle of liquid medication, nutrient, or other fluid through a hollow needle piercing the muscle and any tissue covering it. Intramuscular Injections,Injection, Intramuscular,Intramuscular Injection
D008297 Male Males
D008525 Medroxyprogesterone A synthetic progestational hormone used in veterinary practice as an estrus regulator. (6 alpha)-17-Hydroxy-6-methylpregn-4-ene-3,20-dione,Methylhydroxyprogesterone,Pregn-4-ene-3,20-dione, 17-hydroxy-6-methyl-, (6alpha)-,17 alpha-Hydroxy-6 alpha-Methylprogesterone,Adgyn Medro,17 alpha Hydroxy 6 alpha Methylprogesterone
D001827 Body Height The distance from the sole to the crown of the head with body standing on a flat surface and fully extended. Body Heights,Height, Body,Heights, Body
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D004394 Dydrogesterone A synthetic progestational hormone with no androgenic or estrogenic properties. Unlike many other progestational compounds, dydrogesterone produces no increase in temperature and does not inhibit OVULATION. Isopregnenone,6-Dehydro-9 beta-10 alpha-progesterone,Dehydrogesterone,Duphaston,6 Dehydro 9 beta 10 alpha progesterone
D004997 Ethinyl Estradiol A semisynthetic alkylated ESTRADIOL with a 17-alpha-ethinyl substitution. It has high estrogenic potency when administered orally, and is often used as the estrogenic component in ORAL CONTRACEPTIVES. 19-Norpregna-1,3,5(10)-trien-20-yne-3,17-diol, (17alpha)-,Ethynyl Estradiol,Estinyl,Ethinyl Estradiol Hemihydrate,Ethinyl Estradiol, (8 alpha)-Isomer,Ethinyl Estradiol, (8 alpha,17 alpha)-Isomer,Ethinyl Estradiol, (8 alpha,9 beta,13 alpha,14 beta)-Isomer,Ethinyl Estradiol, (9 beta,17 alpha)-Isomer,Ethinyl-Oestradiol Effik,Ethinylestradiol Jenapharm,Ethinyloestradiol,Lynoral,Microfollin,Microfollin Forte,Progynon C,Estradiol, Ethinyl,Estradiol, Ethynyl,Ethinyl Oestradiol Effik,Hemihydrate, Ethinyl Estradiol,Jenapharm, Ethinylestradiol
D005260 Female Females
D006130 Growth Disorders Deviations from the average values for a specific age and sex in any or all of the following: height, weight, skeletal proportions, osseous development, or maturation of features. Included here are both acceleration and retardation of growth. Stunted Growth,Stunting,Disorder, Growth,Growth Disorder,Growth, Stunted,Stuntings

Related Publications

W J de Waal, and S de Muinck Keizer-Schrama, and S L Drop
May 1998, Nederlands tijdschrift voor geneeskunde,
W J de Waal, and S de Muinck Keizer-Schrama, and S L Drop
January 1989, Pediatriia,
W J de Waal, and S de Muinck Keizer-Schrama, and S L Drop
October 2012, BMJ case reports,
W J de Waal, and S de Muinck Keizer-Schrama, and S L Drop
April 2003, The Journal of clinical endocrinology and metabolism,
W J de Waal, and S de Muinck Keizer-Schrama, and S L Drop
June 2004, Clinical endocrinology,
W J de Waal, and S de Muinck Keizer-Schrama, and S L Drop
January 1989, Pediatriia,
W J de Waal, and S de Muinck Keizer-Schrama, and S L Drop
April 2004, Endocrine journal,
W J de Waal, and S de Muinck Keizer-Schrama, and S L Drop
April 2006, Clinical endocrinology,
W J de Waal, and S de Muinck Keizer-Schrama, and S L Drop
July 1982, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme,
W J de Waal, and S de Muinck Keizer-Schrama, and S L Drop
January 1988, European journal of pediatrics,
Copied contents to your clipboard!